News from xtl biopharmaceuticals ltd A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 02, 2014, 12:09 ET

XTL Biopharmaceuticals Provides Financial and Operational Update for the Second Quarter of 2014

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...

Jun 12, 2014, 08:00 ET

XTL Biopharmaceuticals Receives Correspondence Regarding Nasdaq Listing Requirements

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...

Jun 02, 2014, 09:00 ET

XTL Biopharmaceuticals Reports Financial and Operational Results for the First Quarter of 2014

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...

May 19, 2014, 08:00 ET

XTL Biopharmaceuticals Further Strengthens Team for Phase II Lupus Trial with Two Additional Experts

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...

Apr 02, 2014, 16:41 ET

XTL Biopharmaceuticals Reports Financial and Operational Results for the Full Year Ended 2013

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...

Mar 25, 2014, 08:00 ET

XTL Biopharmaceuticals Retains Expert Consultants in Rheumatology for Phase II Lupus Trial

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...

Jan 08, 2014, 08:00 ET

XTL Biopharmaceuticals In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...

Jul 15, 2013, 13:30 ET

XTL Biopharmaceuticals' ADRs Commence Trading on NASDAQ Stock Market

XTL Biopharmaceuticals, Ltd. (NASDAQ: XTLB) (TASE: XTL) (the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition,...

Jul 10, 2013, 13:45 ET

XTL Biopharmaceuticals Returns to NASDAQ

XTL Biopharmaceuticals Ltd. (the "Company") (TASE: XTL), (OTC: XTLBY) announced today that NASDAQ approved the Company's listing application and...

Dec 05, 2012, 11:20 ET

Following the Acquisition of the Controlling Stake by XTL, Proteologics Appoints Board Members and Chairman

XTL Biopharmaceuticals Ltd (TASE: XTL) (OTC: XTLBY) (the "Company", or "XTL"), a biopharmaceutical development company that recently acquired the...

Nov 26, 2012, 16:21 ET

XTL Biopharmaceuticals Acquires Stake in Proteologics Ltd.

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced on November...

Oct 04, 2012, 14:51 ET

XTL Biopharmaceuticals Effectuates ADR Ratio Change

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced today that following the...

Oct 04, 2012, 12:18 ET

XTL Biopharmaceuticals Effectuates ADR Ratio Change

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced today that following the...

Sep 24, 2012, 17:00 ET

Strategic Online Marketing Agreement signed by InterCure, XTL Biopharmaceuticals' Subsidiary

XTL Biopharmaceuticals Ltd. ("XTL") today announced that InterCure Ltd. ("InterCure"), which is approximately 45.4% (50.79% on a fully diluted...

Sep 24, 2012, 12:57 ET

XTL Biopharmaceuticals Provides Favorable Update on NASDAQ Listing Process

 XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced today that it...

Jun 19, 2012, 10:14 ET

XTL Biopharmaceuticals to Acquire Kitov Pharmaceuticals

XTL Biopharmaceuticals Ltd. (TASE:XTL)(OTC:XTLBY), a biopharmaceutical development company, announced today it will acquire Kitov...

Jun 11, 2012, 14:59 ET

XTL Biopharmaceuticals Joins Two Additional Indexes on TASE

XTL Biopharmaceuticals Ltd. (TASE:XTL,OTC:XTLBY), a biopharmaceutical development company, announces it has been notified by the Tel Aviv Stock...

Jun 04, 2012, 12:22 ET

XTL Biopharmaceuticals Files Application for Listing on the NASDAQ

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced today that it has filed...

Apr 17, 2012, 10:32 ET

XTL Biopharmaceuticals Ltd. Names Dr. Ben-Zion Weiner to its Board of Directors

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced yesterday that Dr....

Apr 16, 2012, 16:16 ET

XTL Biopharmaceuticals Ltd. Signs Letter of Intent to Acquire a Drug Development Company

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (hereinafter, "XTL"), a biopharmaceutical development company, announced yesterday that on...